KEWAUNEE SCIENTIFIC CORP /DE/: management transactions · United States · SEC (Form 4)

About KEWAUNEE SCIENTIFIC CORP /DE/

Kewaunee Scientific Corp /DE/ (ticker: KEQU) is a U.S.-listed industrial company traded on NASDAQ in the United States. Founded in 1906, Kewaunee has built a long-standing niche in the design, manufacture, and installation of laboratory, healthcare, and technical furniture and infrastructure products. For French-speaking investors, it is best viewed as a specialized capital-goods supplier with exposure to structural spending in scientific, educational, healthcare, and research facilities rather than as a broad-based general manufacturer. The company’s core product set includes steel and wood casework, laboratory benches, epoxy resin work surfaces and sinks, fume hoods, adaptable modular systems, moveable workstations, and biological safety cabinets. Beyond the physical furniture line, Kewaunee also provides installation and related project services, which makes its model more integrated than a pure product seller. Its end markets span life sciences, education, government, healthcare, and general research. This end-market mix gives Kewaunee a degree of resilience, since demand is tied to laboratory build-outs, renovations, compliance-driven upgrades, and scientific infrastructure investment. Kewaunee’s headquarters are in Statesville, North Carolina. The company also maintains sales offices in the United States, India, Saudi Arabia, and Singapore, with manufacturing facilities in Statesville and Bangalore, India. That footprint gives Kewaunee a dual identity: a U.S.-anchored industrial base with a meaningful international reach, especially across Asia and into other overseas markets. The company’s local manufacturing presence in India also supports regional customer needs and broadens its ability to serve markets beyond North America. Competitive positioning is driven by specialization, technical credibility, and a reputation for meeting demanding safety and quality standards in laboratory environments. Kewaunee emphasizes collaboration with industry bodies to help shape product standards, which supports its positioning as a trusted supplier in a technically regulated niche. Recent developments have been especially important. In fiscal 2025, Kewaunee reported annual sales of $240.5 million, up 18% year over year, alongside stronger EBITDA performance. A key strategic milestone was the November 1, 2024 acquisition of Nu Aire, which expands the product portfolio into biological safety cabinets, CO2 incubators, ultra-low freezers, and adjacent lab products. Management also reported a backlog of $214.6 million as of April 30, 2025, indicating solid near-term demand visibility. Overall, KEQU looks like a small-cap industrial compounder with a focused market position, acquisition-led growth, and long-duration exposure to laboratory capex cycles in the United States and abroad.